Gene Therapy Market Size, Share, Growth Analysis, By Type(Gene silencing, cell replacement, gene augmentation, other therapies), By Vector(Viral vectors, and non-viral vectors), By Therapeutic Area(Neurology, Oncology, Hepatology, and Other Therapeutic areas), By Route Of Administration(intravenous, and other routes of administration), By Delivery Mode(IN VIVO, and EX VIVO), By Region - Industry Forecast 2024-2031

Global Gene Therapy Market size was valued at USD 7.41 billion in 2022 and is poised to grow from USD 9.0 billion in 2023 to USD 42.46 billion by 2031, at a CAGR of 21.4% during the forecast period (2024-2031).

Numerous key players are driving innovation and market growth in the competitive global gene therapy market. Leading companies include Novartis, who offer Kymriah; Gilead Sciences, with its Yescarta; and Bluebird Bio, which focuses on therapies for genetic diseases. Apart from these, other noteworthy entities are Spark Therapeutics and CRISPR Therapeutics involved in advances in gene editing and delivery technologies. The R&D activities of these firms are intensive aimed at increasing the range of therapeutic indications as well as consolidating their position in the marketplace. 'Novartis AG (Switzerland) ', 'Biogen Inc. (US) ', 'Gilead Sciences, Inc. (US) ', 'Bristol-Myers Squibb (US) ', 'Alnylam Pharmaceuticals, Inc. (US) ', 'Sarepta Therapeutics, Inc. (US) ', 'Amgen, Inc. (US) ', 'Orchard Therapeutics PLC (UK) ', 'F. Hoffmann-La Roche AG (Switzerland) ', 'Jazz Pharmaceuticals PLC (Ireland) ', 'uniQure N.V. (Netherlands) ', 'Johnson & Johnson (US) ', 'bluebird bio, Inc. (US) ', 'BioMarin Pharmaceutical Inc. (US) ', 'Krystal Biotech, Inc. (US) ', 'Shanghai Sunway Biotech Co. Ltd. (China) ', 'Sibiono Genetech Co. Ltd. (China) ', 'Ferring B.V. (Netherlands) ', 'Vertex Pharmaceuticals Incorporated (US) ', 'Pfizer Inc. (US) ', 'Sangamo Therapeutics, Inc. (US) ', 'Regenxbio (US) ', 'Ultragenyx Pharmaceutical Inc. (US) ', 'MeiraGTx Holdings PLC (UK) ', 'AnGes, Inc. (Japan)'

The burgeoning global gene therapy industry is propelled by rapid advancements in gene editing technologies such as CRISPR-Cas9. By improving the accuracy, efficacy and safety of genetic manipulation, these state-of-the-art technologies have expedited clinical development steps and increased the number of options available for patients. In addition, vector-based approaches alongside better delivery systems are aiding this growth. 

The global gene therapy industry is changing because of innovations, advances in genetic research, and growing knowledge of gene-based treatments. Targets for gene therapy are increasingly rare hereditary disorders. As genetic defects causing diseases are identified, gene cures for rare conditions are being created. Those with incurable illnesses now have hope due to the advancement towards more targeted and accurate therapies. 

North America dominates the global gene therapy market size due to its robust infrastructure, substantial investment in research and development, and leading biotech and pharmaceutical companies. The region gets advanced health care systems, top-notch research institutions, while a favorably regulated environment helps spur innovation and hasten clinical trials. High expenditure on healthcare and the growing focus on personalized medicine are driving gene therapy market growth. North America’s leadership in gene therapies is reinforced by major actors in the market and favorable reimbursement policies that make it the leader in terms of gene therapy market progress.